N/A
N=335
BK Virus Infection (Viremia) Natural History in Renal Transplant Recipients
BK Virus (BKV) Viremia
Bottom Line
View on ClinicalTrials.gov: NCT01782209 ↗Enrolled (actual)
335
Serious AEs
0.0%
Results posted
Jul 2020
Primary outcome: Primary: Incidence of BKV Viremia in the Study Population of Screened Renal or Renal-pancreas Transplant Subjects — 58 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Alabama at Birmingham
- Primary completion
- Dec 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence of BKV Viremia in the Study Population of Screened Renal or Renal-pancreas Transplant Subjects |
58 | — |
Summary
The objectives of this study is to establish the natural history of BK virus viremia and other possible opportunistic viral pathogens in renal transplants recipients.
Eligibility Criteria
Inclusion Criteria
Renal or renal-pancreas transplant patients who are within 4 weeks and not more than 90 days post-transplant with or without qualifying BKV viremia Age greater than or equal to 18 years; Provides written informed consent.
Exclusion Criteria
Evidence of proven or suspected BKVN by clinical or pathologic diagnostic criteria Loss of renal graft function Initiation of chronic dialysis
Data sourced from ClinicalTrials.gov (NCT01782209). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.